CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of this study were

* to analyze CD160 expression in both normal and pathological eyes from human adults
* to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retinal Arteriolar Abnormalities and CV Mortality

NCT00011167

Cardiovascular Diseases Heart Diseases Cerebrovascular Disorders +1 more

COMPLETED

Retinal Microvascularization and Cardiovascular Disease

NCT03551717

High Cardiovascular Risk Patients Low Cardiovascular Risk Patients

TERMINATED

Imaging of Retinochoroidal Vasculature in Patients Being Assessed for Cardiovascular Disease

NCT05082402

Cardiovascular Diseases Retina; Change

RECRUITING NA

Retinal Function in Diabetic Patients Without Retinopathy

NCT00839150

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

COMPLETED

Screening for Studies on Retinovascular Diseases

NCT00001733

Diabetic Retinopathy Macular Degeneration Pathologic Neovascularization +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.

CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Retinal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

neovascular group

patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment

immunohistochemistry on Formalin fixed and paraffin embedded blocks

Intervention Type OTHER

non-neovascular group

patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.